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Abstracts / Biol Blood Marrow Transplant 19 (2013) S150eS166S164conditioning regimen consisted of Cyclophosphamide with
either total body irradiation or Busulfan, with the addition of
Fludarabine in 13 patients (62%). In vivo T cell depletion with
Anti-Thymocyte Globulin was performed in 18 patients
(85%), and 11 donor grafts underwent ex vivo T cell depletion
(52%). Donor source included HLA-matched sibling (n¼3),
mismatched related donor (n¼1), unrelated marrow (n¼12)
and unrelated cord blood (n¼5). 58% of unrelated donors had
at least 1 HLA mismatch. Neutrophil engraftment for the
entire cohort was 90%, and 100% for those patients that
received Fludarabine. The incidence of acute GVHD was 19%
for the entire cohort. 5 year Overall Survival (OS) was 32%,
with a relapse rate of 20% (Figure). Of the patients that
received Fludarabine, 5 year OS was 38% with a relapse rate
of 30%. For the patients with biallelic BRCA2 mutation, 5 year
OS was 33% with a relapse rate of 50%
Our study provides evidence for use of HCT with a Flu-
darabine containing regimen for FA patients with acute
leukemia or advanced MDS, who would otherwise have
a dismal prognosis. The role of pre-HCT chemotherapy
remains unclear, and requires further investigation. BRCA2
patients are a unique subset of FA patients and require
tailored therapy to optimize HCT outcomes.
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To identify possible dose related toxicities of treosulfan
containing regimen and determine the incidence of
engraftment, treatment related mortality (TRM), overall
survival (OS) and event free survival (EFS) we explored 616
patients (pts) below 18 years who underwent HSCT between
January 2005 and July 2010 for malignant (n¼ 270, 43%) ornon malignant disease (n ¼ 356, 57%). To investigate
a potential non-linear association between dose and
outcome, fractional polynomials were used.533 pts under-
went allogeneic, 93 autologous HSCT. 513 (83%) pts received
a treosulfan-based conditioning regimen during their ﬁrst
HSCT. 124 (20%) had a matched sibling donor (MSD). The
stem cell source was bone marrow (BM) in 274 pts (44%) and
peripheral blood in 264 pts (42%).In the group of pts with
allogeneic HSCT, 41 were below the age of 6 months and 65
between 6-months and 1 year. 314 were between 1 and 12
years and 101 above 12 years. For allogeneic HSCT, the
median treosulfan dose was 42 g/msq (12-46). 24 pts (5%)
received less then 33 g/msq. 153 pts (29%) received between
33 and 39 g/msq. The majority of pts received a treosulfan
dose between 39 and 45 g/msq.
Results: There is no signiﬁcant correlation of the time to ANC
> 0.5x10e9/L with age and treosulfan-dose. Primary graft
failure occurred in 2% of cases with no signiﬁcant correlation
with age, treosulfan dose and underlying disease in uni- and
multivariate analysis. Acute graft-versus-host disease
(GvHD) of grade III-IV occurred in 10% of the patients and the
rate of limited and extended chronic GvHD was 13% and 6%,
respectively. The most common grade 3 or 4 toxicities were
diarrhoea (24%), stomatitis (22%), and SGOT elevation (25%).
Veno-occlusive disease was described in 5% of all pts. There
was a signiﬁcant association between age and VOD-inci-
dence, with higher VOD-rates in children below the age of
0.5 years (12%), that are exclusively children with non-
malignant diseases. Treosulfan-dose has no signiﬁcant
impact on VOD and GVHD in both univariate and multivar-
iate analysis. There is a border-line signiﬁcant impact of age
on overall survival. The 3-years pOS in children below 6
months, between 6 months and 1 year between 1-12 years
and > 12 years is 75%, 84%, 70% and 60%, respectively. This
difference is mainly caused by a difference in disease related
mortality (DRM). TRM is not signiﬁcantly different in the
different age groups. With respect to dose, we did not ﬁnd
a signiﬁcant impact on overall survival, neither in univariate
nor in adjusted analysis. However, therewas a better OS after
ﬁrst HSCT (0,74%) compared to second or third HSCT (0,51%),
P < .001.
Conclusion: These results emphasise the low toxicity proﬁle
of treosulfan, even in heavily pre-treated children and
adolescents and in patients undergoing a second HSCT. It was
shown that treosulfan is highly efﬁcient to enable engraft-
ment without increasing the risk for severe acute or chronic
GVHD.100
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Background: Myeloablative conditioning with busulfan and
cyclophosphamide (200 mg/kg) (Bu/CY) followed by HLA-
Patient Characteristics by Post-Cy Group
Characteristics Post-Transplant
Cyclophosphamide
P- value*
Yes No
n ¼ 21 % n ¼ 35 %
Age group (years)
0.1-9.9 17 81 26 74 .75
10.0-19 4 19 9 26
F. donor / M receptor 6 29 8 23 .90
Double cord 3 14 3 9 .66
Diagnoses
Acute leukemias 12 57 17 49
Abstracts / Biol Blood Marrow Transplant 19 (2013) S150eS166 S165matched sibling bone marrow transplantation results in
approximately 85% event free survival in high-risk patients
with Sickle Cell Disease (SCD) (Walters, NEJM, 2006).
However, this approach is limited by 5-10% transplant-
related mortality, 5-10% primary graft failure and the late
effects of Bu/CY. Alternate approaches include reduced
toxicity but more immunosuppressive conditioning and the
use of sibling cord blood (Geyer/Cairo, BJH, 2011 and Freed/
Cairo, BMT, 2012).
Objective: To determine the safety, donor chimerism and
long term organ function associated with Bu 12.8-16 mg/kg,
ﬂudarabine180 mg/m2 and alemtuzumab 54 mg/m2 (BFA)
reduced toxicity conditioning (RTC) prior to HLA-matched
sibling donor transplantation in pediatric recipients with
high risk SCD.
Methods: Patients 21 years of age with HbSS, HbSC, HbSb+
or HbSb0 were eligible if highly symptomatic (such as 2
vaso-occlusive crises per year requiring narcotics, acute chest
syndrome, stroke, retinopathy, splenic sequestration) and
with an HLA-matched sibling donor. Conditioning consisted
of busulfan (4mg/kg x 4d < 4 yrs and 12.8mg/ kg x 4d > 4
yrs), ﬂudarabine (30mg/m2 x 6d), and alemtuzumab (2mg/
m2 x 1d, 6mg/m2 x 2d, and 20mg/m2x 2d) as we have
described (Styczynski/Cairo,BMT,2011). All received tacroli-
mus and MMF as GVHD prophylaxis as we have described
(Bhatia/Cairo, BBMT, 2010).
Results: 12 patients (11M:1F), median age 12 (2-19) with
symptomatic SCD underwent sibling BM (n¼10) or CB (n¼2)
Allogeneic Stem Cell Transplantation (AlloSCT). Median
follow-up was 33 months. Median time to neutrophil and
platelet engraftment for recipients of sibling BM and CBwere
16 days (13-18), 18.5 days (9-43) and 39.5 days (38-41) and
74 days (73-75), respectively. The probability of grade II-IV
and grade III-IV aGVHD were 16.7% and 8.3%. No patients
developed cGVHD. Patients achieved mean whole-blood
donor chimerism of 85, 94, 93, 93, 89 and 93% and mean
erythroid (CD71) donor chimerism of 89, 89, 93, 90, 86, and
94% at days 30, 60, 100, 180, 365 and 730 post-transplant,
respectively. The Kaplan-Meier probability of OS and EFS was
100% (CI95: 73.5-100%). Neurological, pulmonary, vascular,
and splenic function were stable to improved at 2 years.
Conclusions: BFA (RTC) and HLA-matched sibling bone
marrow and cord blood AlloSCT in pediatric recipients
results in excellent EFS, long term donor chimerism, and
stable/improved organ function.SAA 3 14 8 23 .58
Others 6 29 10 29
RIC 7 33 16 46 .41
TBI 12 57 22 63 .78
ATG or Alemtuzumb 6 29 17 49 .17
HLA match (n¼52)
6/6 1 5 6 19
5/6 9 50 11 34 .31
4/6 10 45 15 47
Receptor CMV (+) 21 100 30 86 .14
CMV viremia 13 62 19 54 .78
Invasive mycosis 4 19 6 17 .99101
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Post-transplant Cyclophosphamide (Post-Cy) has demon-
strated to decrease the occurrence of aGVHD inpreclinical and
haploidentical studies. Nevertheless, Post-Cy increases time to
neutrophil recovery, an issue that is of utmost importance for
UCB transplant related mortality (TRM). We postulated that
despite UCB lower cellular doses, the use of Post-Cy decreases
graft vs host and host vs graft reactions, enhancing engraft-
ment, and improving clinical outcomes. So we explore the
feasibility of using Post-Cy in the setting of UCB trans-
plantation in children. In June/2010, our group decided to
include post-Cy for UCB transplantation. A single 50 mg/kg/
dose of Cywas addedonday +3. CSA andMMFwas started day+4, as well as G-CSF. Post-Cy was used both in RIC and mye-
loablative transplants. Rabbit ATG or Alemtuzumab was used
only for RIC transplants. The group that received Cy-Post (21
cases) was compared with our previous UCB transplantation
cases (35 cases) where Post-Cy was not used. Multivariate
logistic regression models were used to evaluate the inde-
pendence of the relationship between Cy-Post and aGvHD, of
other covariates such as, age, gender, RIC, HLA match, CMV
receptor status, pre-freezing TNC and CD34. Attached table
compares characteristics ofpatientswith andwithout Post-Cy.
No signiﬁcant differenceswere identiﬁed among the 2 groups.
The groupswith andwithout Post-Cywere infusedwith 7.1 vs
6.4x107 TNC/kg, and 2.84 vs 2.81x105 CD34+cells/kg, respec-
tively. 100-day (25% vs 26%) and 1-year (25% vs 31%) TRM and
overall survival (60% vs 57%) were not different among the
groups. Median time to neutrophil and platelet engraftment
with andwithout Post-Cywas24vs 16days (P< .01), and43vs
35 days (P¼0.02), respectively. Forty-nine (87.5%) patients
were evaluable for aGvHD, 49% were classiﬁed as grades II-IV.
In the group with Post-Cy grades II-IV aGvHD was 32%
comparedwith 68% in the groupwithout Post-Cy. ORwas 0.31
(95%CI:0.1, 1.0), and adjusted OR was 0.16 (95%CI: 0.03, 0.78),
P¼ .02. Nodocumented cases of grade IV aGvHD in thePost-Cy
group. In conclusion, we found an important effect of Post-Cy
over the occurrence of aGVHD, independently of HLA match,
and of other relevant variables. Neither, we ﬁnd an effect over
earlyTRM,and isuncertain its impactover long termmortality.
We hypothesize that usage of Post-Cy in UCB transplantation
in children, can allow the use of UCB units with greater HLA
mismatch, and thus, increasing the potential pool of grafts
available for transplantation. This couldbeespeciallyuseful for
ethnic minorities.* Fisher’s exact two sided test.102
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